This site is intended for health professionals only
Monday 22 October 2018
Share |

OZURDEX® significantly improves vision in real-life study

New study supports earlier intervention in DMO

New data published from the University of Barcelona shows OZURDEX® (dexamethasone 0.7mg intravitreal implant) provides significant improvements in visual acuity, compared to baseline, in patients affected by diabetic macular oedema (DMO). This was observed in patients that had not responded to two or more DMO treatments (refractory, n=40), as well as in those that had not previously received DMO therapy (treatment-naïve, n=36). (1)

Ads by Google